

# Report of Investigation

# Reference Material 8321

# Peptide Mixture for Proteomics

This Reference Material (RM) is intended to support investigations used to identify peptides in complex peptide mixtures such as those in mass spectrometry-based proteomics. RM 8321 can be used to help assess the confidence of peptide identification within a laboratory or comparability between laboratories or among different measurement approaches. RM 8321 can also be used in the development and validation of new investigative approaches for identifying peptides in complex peptide mixtures. A unit of RM 8321 consists of three vials, each containing approximately  $50 \,\mu\text{L}$  of frozen aqueous solution containing  $0.1 \,\text{mL/L}$  formic acid. The peptides in this RM are estimated to be in a concentration range of  $0.1 \,\text{pmol/}\mu\text{L}$  to  $10 \,\text{pmol/}\mu\text{L}$ .

RM 8321 is an aqueous solution of approximately 440 synthetic peptides, present at a range of concentrations that span approximately three orders of magnitude. RM 8321 was designed to provide a complex mixture of peptides for evaluating the performance of proteomics mass spectrometry instruments coupled to liquid chromatography (LC) [1]. Peptides were chosen to cover the chromatographic "space" of a typical reverse phase gradient elution analysis, offering a range of elution profiles. The synthetic peptides in RM 8321 have the same amino acid sequence as tryptic peptides from 50 high abundance human plasma proteins that have been observed as proteotypic peptides through multiple published investigations by the proteomics community. Proteotypic peptides are those peptides which are observed repeatedly by mass spectrometric-based proteomics investigations by different investigators. Therefore, proteotypic peptides are expected to be readily released from enzymatic digestions of the precursor protein, ionize well by electrospray ionization, generate high quality tandem mass spectrometry (MS/MS) spectra, and are stable during the processes of sample preparation and analysis.

**Reference Values:** A NIST reference value represents the best estimation of the true value based upon the available data [2]. Table 1 lists a set of heuristic rules which describe the confidence of peptide identification in RM 8321. Table 2 lists the peptides present, grouped by confidence level, as determined by two types of LC-MS/MS analyses and comparison to mass spectral libraries [3].

**Expiration of Reference Values:** RM 8321 is valid, within the specified confidence levels, until 05 June 2020, provided the RM is handled and stored in accordance with the instructions given in this report (see "Instructions for Storage and Use"). This report is nullified if the RM is damaged, contaminated, or otherwise modified.

**Maintenance of RM:** NIST will monitor this RM over the period of its validity. If substantive technical changes occur that affect the value assignment before the expiration of this report, NIST will notify the purchaser. Registration (see attached sheet or register online) will facilitate notification.

Overall direction and coordination of technical measurements leading to peptide identification were performed by D.M. Bunk of the NIST Biomolecular Measurement Division.

Analyses were performed by A.S. Beasley, M. Lowenthal, and D.M. Bunk of the NIST Biomolecular Measurement Division.

Support aspects involved in the issuance of this RM were coordinated through the NIST Office of Reference Materials.

Michael J. Tarlov, Chief Biomolecular Measurement Division

Gaithersburg, MD 20899

Report Issue Date: 28 December 2015

Robert L. Watters, Jr., Director
Office of Reference Materials

RM 8321 Page 1 of 5

**Reference Values:** Table 1 defines the corresponding confidence levels of peptide identification in RM 8321. Table 2 identifies the peptide content, grouped by confidence level, based on both the data dependent acquisition (DDA) and dynamic multiple reaction monitoring (dMRM) analyses.

Table 1. Definitions of Heuristic Rules

Confidence Level	Heuristic Definition	
High Confidence	Peptides listed were observed in more than 90 % of all laboratory investigations (including technical and process replicate analyses).	
Confident	Peptides listed were observed in more than 50 $\%$ and less than 90 $\%$ of all laboratory investigations.	
Low Confidence	Peptides listed were observed in less than 50 % of all laboratory investigations.	

Table 2. Reference Peptide Content of RM 8321				
High Confidence:				
AATVGSLAGQPLQER	HLSLLTTLSNR	SDVVYTDWKKDK		
ADLFYDVEALDLESPK	HLVPGAPFLLQALVR	SEETKENEGFTVTAEGK		
AEDHFSVIDFNQNIR	HPDYSVVLLLR	SELEEQLTPVAEETR		
AEFAEVSK	HQLYIDETVNSNIPTNLR	SELTQQLNALFQDK		
AFQPFFVELTMPYSVIR	HQTVPQNTGGKNPDPWAK	SFFSFLGEAFDGAR		
AGALNSNDAFVLK	HSIFTPETNPR	SGAQATWTELPWPHEK		
AGDFLEANYMNLQR	HSTIFENLANK	SGFPQVSMFFTHTFPK		
AGKEPGLQIWR	HTLNQIDEVK	SGKDPNHFRPAGLPEK		
AHVSFKPTVAQQR	HTSVQTTSSGSGPFTDVR	SGVQQLIQYYQDQK		
AHYGGFTVQNEANK	HVVPNEVVVQR	SHALQLNNR		
AIEDYINEFSVR	HYEGSTVPEK	SIEVFGQFNGK		
AIGYLNTGYQR	HYQINQQWER	SKEFQLFSSPHGK		
AKPALEDLR	IADAHLDR	SKEQLTPLIK		
ALDLINKR	IADNKQSSFK	SLAELGGHLDQQVEEFRR		
ALLVGEHLNIIVTPK	IAFSATR	SLAPYAQDTQEK		
ALMDETMK	IAQWQSFQLEGGLK	SLHTLFGDK		
ALTDMPQMR	IDTQDIEASHYR	SPELQAEAK		
ALVQQMEQLR	IEGNLIFDPNNYLPK	SPELQAEAKSYFEK		
ALYLQYTDETFR	IHWESASLLR	SSALDMENFR		
AMAVEDIISR	IIRSSEDPNEDIVER	SSEDPNEDIVER		
APNHAVVTR	IIVPLNNR	SSLSVPYVIVPLK		
AQLVDMK	IKVLNQELR	SSNLIILEEHLK		
AQRQVVAGLNFR	ILGGHLDAK	SVLGQLGITK		
ASEAEDASLLSFMQGYMK	IPIEDGSGEVVLSR	SVNDLYIQK		
ASSIIDELFQDR	IPLDLVPK	SVSDGIAALDLNAVANK		
ASSIIDELFQDRFFTR	ISASAEELR	SVVDENFSWYLEDNIK		
ASTPNGYDNGIIWATWK	ISEGLPALEFPNEK	SYFEKSKEQLTPLIK		
ATEHLSTLSEK	ITENDIQIALDDAK	SYFPESWLWEVHLVPR		
ATFQTPDFIVPLTDLR	ITPNLAEFAFSLYR	SYTITGLQPGTDYK		
ATGVLYDYVNK	IVSSAMEPDR	TAAQNLYEK		
ATVVYQGER	IYGNQDTSSQLKK	TAAQNLYEKTYLPAVDEK		
AVMDDFAAFVEK	IYHSHIDAPK	TAGWNIPMGLLYNK		
AVSMPSFSILGSDVR	IYISGMAPRPSLAK	TDAPDLPEENQAR		
AYKSELEEQLTPVAEETR	IYLYTLNDNAR	TEDTIFLR		
DALSSVQESQVAQQAR	KAMAVEDIISR	TEGDGVYTLNDK		
DAQYAPGYDKVK	KATVVYQGER	TEHPFTVEEFVLPK		
DDEEFIESNK	KDNEQHVFK	TEHYEEQIEAFK		
DDNPNLPR	KELSSFIDK	TELRPGETLNVNFLLR		
DFHINLFQVLPWLK	KFPSGTFEQVSQLVK	TEVNVLPGAK		
DFVQPPTK	KGEWVALNPLR	TGAQELLR		
DGAGDVAFVK	KLSSWVLLMK	TGLQEVEVK		
DGNTLTYYR	KLVPFATELHER	THLAPYSDELR		
DHAVDLIQK	KLWAYLTINQLLAER	THLPEVFLSK		

RM 8321 Page 2 of 5

**High Confidence (continued):** 

DINYVNPVIK THLPEVFLSKVLEPTLK KSASDLTWDNLK **DISEVVTPR** TILGTMPAFEVSLQALQK KTLLSNLEEAKK **DKVNSFFSTFK KVEOAVETEPEPELR TLEAQLTPR** DLATVYVDVLK KVPQVSTPTLVEVSR **TLLPVSKPEIR KWQEEMELYR DLKVEDIPLAR TLLSNLEEAK** DLMEKVKSPELOAEAK **KYFIDFVAR** TMEQFTIHLTVNPQSK KYNSQNQSNNQFVLYR DMYSFLEDMGLK TMTIHNGMFFSTYDR **DRVVEESELAR** LANLTOGEDOYYLR **TNFDNDIALVR** DSGRDYVSOFEGSALGK LAVYOAGAR TPSAAYLWVGTGASEAEK DSQEEEKTEALTSAK **LDAQASFLPK TSNFNAAISLK** DSOEEEKTEALTSAKR **LDELRDEGK** TTIEKPVWLGFLGPIIK DTVIKPLLVEPEGLEK LDEVKEQVAEVR TTNIQGINLLFSSR DTVQIHDITGK **LDGKFSVVYAK TVGSDTFYSFK DVVLFEK LDGSVDFK TVIGPDGHK** DWHGVPGQVDAAMAGR **LDGSVDFKK TVMVNIENPEGIPVK DYWSTVK LEEQAQQIR TWRNDLISATK EAOLPVIENK** LFDSDPITVTVPVEVSRK **TYETTLEK EDLIWELLNQAQEHFGK** LGPHAGDVEGHLSFLEK **TYLPAVDEK EDTPNSVWEPAK LGPLVEQGR TYLPAVDEKLR EELLPAODIK LGOYASPTAK** TYLPAVDEKLRDLYSK **EESPLLIGQQSTVSDVPR** LGVRPSQGGEAPR **TYMLAFDVNDEK EFQLFSSPHGK** LHEAFSPVSYQHDLALLR **TYNVLDMK VDKDNEDFQESNR ELDESLQVAER** LHIMAGR **ELSSFIDK** LKEEIGKELEELR VDVIPVNLPGEHGQR **ELSYYSLEDLNNK** LKNSLFEYQK VEDPESTLFGSVIR **EMSGSPASGIPVK** LKSWFEPLVEDMQR VFDEFKPLVEEPQNLIK **ENADSLQASLRPHADELK** LLDNWDSVTSTFSK VFSNGADLSGVTEEAPLK **ENISDPTSPLR** LLIYAVLPTGDVIGDSAK **VGDTLNLNLR EPAHLMSLFGGKPMIIYK** LNAENNATFYFK VGFYESDVMGR **EPTMYVGSTSVQTSR LPPNVVEESAR VGPEADKYR EQLGPVTQEFWDNLEK LQAEAFQAR** VGYVSGWGR **ESDTSYVSLK LQGTLPVEAR** VIGNMGQTMEQLTPELK LQHLENELTHDIITK **ESYSGVTLDPR** VKDISEVVTPR **ETAVDGELVVLYDVK** VKDLATVYVDVLK **LRDLYSK** LREQLGPVTQEFWDNLEK VKSPELQAEAK **EVAFDLEIPK** LRTEGDGVYTLNDKK VKSPELQAEAKSYFEK **EVDLKDYEDQQK** LSINTHPSQKPLSITVR VLEPTLK **EWFWDLATGTMK EYVLPSFEVIVEPTEK LSNENHGIAQR VLNQELR FAFNLYR** LSPIYNLVPVK VLSLAQEQVGGSPEK **FEDGVLDPDYPR** LTIGEGQQHHLGGAK VLVDHFGYTK LVAYYTLIGASGOR **VMDKYTFELSR FFHKNEIWYR FKDLGEENFK** LVDKFLEDVKK VNKDDEEFIESNK FLATTPNSLLVSWQPPR LVNEVTEFAK **VPEARPNSMVVEHPEFLK** LVTDLTK VPGLYYFTYHASSR **FMETVAEK FNAVLTNPOGDYDTSTGK** LWAYLTIQELLAK **VPGTSTSATLTGLTR FPEVDVLTK** MATTMIQSK VPLLLSEPINIIDALEMR **FPSGTFEQVSQLVK MGPTELLIEMEDWK VPQVSTPTLVEVSR FPVEMTHNHNFR MGPTELLIEMEDWKGDK** VQHIQLLQK **FQNSAILTIQPK** MKGLIDEVNQDFTNR **VQPYLDDFQK FSVPAGIVIPSFQALTAR MKPVPDLVPGNFK** VRGGEGTGYFVDFSVR **FSVVYAK MVETTAYALLTSLNLK** VSFLSALEEYTK **FSYSKNETYQLFLSYSSK MYLGYEYVTAIR** VTIMWTPPESAVTGYR **FSYSSGHVHLSSENK** NANFKFTDHLK VTWAPPPSIDLTNFLVR **FTNIGPDTMR NFPSPVDAAFR VVGGLVALR FTVDRPFLFLIYEHR NGNMAGISDQR VVLHPNYSQVDIGLIK FVTWIEGVMR NHMQYEIVIK VWVYPPEKK FYNQVSTPLLR** NKPGVYTDVAYYLAWIR **VWVYPPEKK NNKDSHSLTTNIMEILR GAYPLSIEPIGVR** VYKPSAGNNSLYR **GDKVWVYPPEKK NPANPVOR** VYSLNDDLKPAK **GDSGGAFAVQDPNDK NPNLPPETVDSLK** WFYIASAFR WKNFPSPVDAAFR **GDSGGPLIVHK NSLFEYQK** 

RM 8321 Page 3 of 5

**High Confidence (continued):** 

**GDSGGPLIVHKR** NWGLSVYADKPETTK WLPSSSPVTGYR **GDSPASSKPISINYR NWIOYK WQEEMELYR GDVAFVK NYNLVESLK** WSRPOAPITGYR **GETHEQVHSILHFK PALPAGTEDTAKEDAANR** WYEIEKIPTTFENGR **GEVQAMLGQSTEELR PLVEEPONLIK** YEASILTHDSSIR GEVQAMLGQSTEELRVR **PNSMVVEHPEFLK** YEFLNGR **GEWVALNPLR** YEITTIHNLFR **PPEIAHGYVEHSVR GFEPTLEALFGK PYTFHSHGITYYK** YFIDFVAR GFSLDEATNLNGGLLR **OFSFPLSSEPFOGSYK** YGLVTYATYPK **GGEGTGYFVDFSVR QGHNSVFLIK** YGMVAQVTQTLK **GGETAOSADPOWEOLNNK** RHPDYSVVLLLR YKEENDDFASFRVDR **GGYTLVSGYPK** RHPYFYAPELLFFAK YLGEEYVK **GHLFLQTDQPIYNPGQR** YLQEIYNSNNQK **RLDGSVDFK GHMLENHVER** RLDGSVDFKK YLQEIYNSNNQKIVNLK **GKWERPFEVK RLEVDIDIK** YLYEIAR **RPYFPVAVGK** YNPVVIDFEMQPIHEVLR **GSESGIFTNTK GSFEFPVGDAVSK** ROSEDSTFYLGER YOISVNK RRDGYLFQLLR **YTFELSR GSPAINVAVHVFR** RSFFSFLGEAFDGAR YVGGQEHFAHLLILR GWVTDGFSSLK **GWVTDGFSSLKDYWSTVK RTHLPEVFLSK** YVLPNFEVK **GYSIFSYATK RVDTVDPPYPR** YVNKEIQNAVNGVK **HGGLYHENMR RVEPYGENFNK** YYTYLIMNK HLEVDVWVIEPQGLR **RYIETDPANR** 

## **Confident:**

**AHVDALR FNKPFVFLMIEQNTK** NRDVVLTTTFVDDIK **ALFVSEEEKK GDKVWVYPPEK RODNEILIFWSK** ALVEGVDQLFTDYQIK **GETHEOVHSILHFK** RTHLPEVFLSKVLEPTLK **AYYENSPQQVFSTEFEVK GSPAINVAVHVFRK** SDVVYTDWK **DGYLFOLLR GSWVNKFPVEMTHNHNFR SDVVYTDWKK** DIFTGLIGPMK **HGTDDGVVWMNWK** SIEVFGOFNGKR DLEIEVVLFHPNYNINGK **HTSLGPLEAK** SKEQLTPLIKK DNDGWLTSDPR **IPKSDVVYTDWKK SWFEPLVEDMOR** DNENVVNEYSSELEK **IPTTFENGR** SYFEKSKEQLTPLIKK **IQPSGGTNINEALLR DNEQHVFK TLLSNLEEAKK** DRLDEVKEQVAEVR **KGEWVALNPLRK TVIGPDGHKEVTK DSAHGFLK** KTLLSNLEEAK **VDTVDPPYPR DSGFQMNQLR** LDDDLEHQGGHVLDHGHK VQFELHYQEVK DTEEEDFHVDOVTTVK LEOGENVFLOATDK VTFOLTYEEVLK DYVSOFEGSALGK LLPHANEVSQK WDPYKQGFGNVATNTDGK LSPLGEEMR ERGHMLENHVER WFYIASAFRNEEYNK **ESLSSYWESAK** LSSPAVITDK YVGGOEHFAHLLILRDTK **EYHFGQAVR MLTPEHVFIHPGWK** 

# Low Confidence:

DVVLTTTFVDDIK PVWLGFLGPIIK TEGDGVYTLNNEK
EDFTSLSLVLYSR SNLDEDIIAEENIVSR VELEDWNGR

RM 8321 Page 4 of 5

#### INSTRUCTIONS FOR STORAGE AND USE

**Handling:** RM 8321 is a frozen aqueous solution containing approximately 440 synthetic peptides in 0.1 mL/L formic acid. Normal caution and care should be exercised during the material's handling and use.

**Storage:** The peptide mixture solution is shipped frozen (on dry ice) and, upon receipt, should be stored frozen until ready for use. A freezer temperature of -20 °C is acceptable for storage for up to one week. If a longer storage time is anticipated, the material should be stored at or below -60 °C. The RM should not be exposed to sunlight or ultraviolet radiation. Storage of thawed material at room or refrigerator temperatures may result in degradation or modification of constituent peptides.

**Use:** Vials of the RM to be analyzed should be removed from the freezer and allowed to stand at room temperature (20 °C to 25 °C) until thawed. After the material is thawed, it should be used immediately. The material should be mixed briefly with a vortex mixer before aliquots are withdrawn.

## PREPARATION AND ANALYSIS(1)

Material Acquisition and Preparation: The synthetic peptides used in the preparation of the RM were obtained from GenScript USA Inc. (Piscataway, NJ). Aqueous solutions of each synthetic peptide were prepared and characterized by LC-MS using a time-of-flight mass analyzer and by LC-MS/MS using an ion trap mass analyzer. Each synthetic peptide was assessed for identify, purity, and its chromatographic and mass spectrometric behavior. Based on this assessment, solutions of 440 synthetic peptides were blended together to produce the peptide mixture in RM 8321. Two additional LC-MS/MS analyses were performed on the RM to confirm the presence of each expected peptide. Using DDA, the RM was analyzed using reversed-phase LC coupled to a LTQ XL (Thermo Scientific) ion trap mass spectrometer. The data from the DDA was analyzed using theoretical fragmentation libraries of tryptic peptides from all human proteins and a library containing only the peptides used to prepare the RM. The data from the ion trap analysis was also searched using a mass spectral library containing only spectra from the peptides used to prepare the RM. In addition to the ion trap analysis, the presence of peptides in the RM was also confirmed through analysis using reversed-phase LC coupled to a model 6460 (Agilent Technologies) triple quadrupole mass spectrometer operated in dMRM mode. The dMRM method monitored three different MRM transitions for each of the expected peptides in the RM.

**Homogeneity Analysis:** The homogeneity was assessed at the time the analyses for the reference peptide content of the RM were performed. A stratified random sampling plan was devised to test for homogeneity across the production lot. The results indicated that no appreciable vial-to-vial differences were detected.

## **REFERENCES**

- [1] Rudnick, P.A.; Clauser, K.R.; Kilpatrick, L.E.; Tchekhovskoi, D.V.; Neta, P.; Blonder, N.; Billheimer, D.D.; Blackman, R.K.; Bunk, D.M.; Cardasis, H.L.; Ham, A.J.; Jaffe, J.D.; Kinsinger, C.R.; Mesri, M.; Neubert, T.A.; Schilling, B.; Tabb, D.L.; Tegeler, T.J.; Vega-Montoto, L.; Variyath, A.M.; Wang, M.; Wang, P.; Whiteaker, J.R.; Zimmerman, L.J.; Carr, S.A.; Fisher, S.J.; Gibson, B.W.; Paulovich, A.G.; Regnier, F.E.; Rodriguez, H.; Spiegelman, C.; Tempst, P.; Liebler, D.C.; Stein, S.E.; *Performance Metrics for Liquid Chromatography-Tandem Mass Spectrometry Systems in Proteomics Analyses*; Mol. Cell Proteomics, Vol. 9(2), pp. 225–241 (2010).
- [2] May, W.; Parris, R.; Beck II, C.; Fassett, J.; Greenberg, R.; Guenther, F.; Kramer, G.; Wise, S.; Gills, T.; Colbert, J.; Gettings, R.; MacDonald, B.; *Definition of Terms and Modes Used at NIST for Value Assignment of Reference Materials for Chemical Measurements*; NIST Special Publication 260-136 (2000); available at http://www.nist.gov/srm/upload/SP260-136.PDF (accessed Dec 2015).
- [3] Stein, S.; Mass Spectral Reference Libraries: An Ever-Expanding Resource for Chemical Identification; Anal. Chem., Vol. 84(17), pp. 7274–7282 (2012).

Users of this RM should ensure that the Report of Investigation in their possession is current. This can be accomplished by contacting the SRM Program: telephone (301) 975-2200; fax (301) 948-3730; e-mail srminfo@nist.gov; or via the Internet at http://www.nist.gov/srm.

RM 8321 Page 5 of 5

-

<sup>(1)</sup> Certain commercial equipment, instruments, or materials are identified in this report to adequately specify the experimental procedure. Such identification does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment identified are necessarily the best available for the purpose.